Pfizer: positive data on pneumococcal vaccine
(CercleFinance.com) - On Monday Pfizer reported positive Phase 3 results from its European study of its proposed paediatric pneumococcal vaccine, which is designed to protect against 20 serotypes of the bacteria.
The trial showed that the so-called "20-valent" conjugate vaccine, called 20vPnC, protected infants vaccinated in a three-dose regimen.
The vaccine is intended for active immunisation of babies under one year of age to prevent pneumonia, but also sepsis and meningitis caused by streptococcus pneumoniae.
Pfizer says it plans to submit this data to the European Medicines Agency (EMA) by the end of the year.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The trial showed that the so-called "20-valent" conjugate vaccine, called 20vPnC, protected infants vaccinated in a three-dose regimen.
The vaccine is intended for active immunisation of babies under one year of age to prevent pneumonia, but also sepsis and meningitis caused by streptococcus pneumoniae.
Pfizer says it plans to submit this data to the European Medicines Agency (EMA) by the end of the year.
Copyright (c) 2022 CercleFinance.com. All rights reserved.